March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, announced the close of a $28.4 million oversubscribed Series A financing. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments.

Existing investors TMC Venture Fund, Cancer Focus Fund, Small Ventures, and Portal Innovations also participated in the round. March Bio has raised over $51 million to date inclusive of all dilutive and non-dilutive funding.